Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 1,603 Shares

Key Points

• Natera CEO Steven Leonard Chapman sold 1,603 shares for $301,283.85 on October 21, reducing his ownership to 155,855 shares.
• The company's stock has a market capitalization of $25.81 billion and has recently traded around $188.02.
• Analysts have given Natera an average target price of $196.81, with most issuing Buy ratings.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 1,603 shares of the stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $187.95, for a total value of $301,283.85. Following the sale, the chief executive officer directly owned 155,855 shares in the company, valued at $29,292,947.25. This trade represents a 1.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, October 1st, Steven Leonard Chapman sold 14,083 shares of Natera stock. The shares were sold at an average price of $160.00, for a total value of $2,253,280.00.
• On Tuesday, September 30th, Steven Leonard Chapman sold 9,109 shares of Natera stock. The shares were sold at an average price of $162.05, for a total value of $1,476,113.45.
• On Tuesday, September 2nd, Steven Leonard Chapman sold 5,079 shares of Natera stock. The shares were sold at an average price of $166.53, for a total value of $845,805.87.
• On Friday, August 1st, Steven Leonard Chapman sold 5,807 shares of Natera stock. The shares were sold at an average price of $132.88, for a total value of $771,634.16.
• On Monday, July 28th, Steven Leonard Chapman sold 6,092 shares of Natera stock. The shares were sold at an average price of $139.81, for a total value of $851,722.52.

Natera Price Performance

Shares of Natera stock traded up $1.14 during trading on Wednesday, hitting $188.02. 1,333,479 shares of the company's stock traded hands, compared to its average volume of 1,160,110. Natera, Inc. has a 1 year low of $117.27 and a 1 year high of $196.63. The stock has a market capitalization of $25.81 billion, a P/E ratio of -98.44 and a beta of 1.74. The business has a 50-day simple moving average of $169.97 and a 200-day simple moving average of $159.37.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The firm had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company's revenue for the quarter was up 32.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. On average, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Several hedge funds have recently made changes to their positions in the company. Guided Capital Wealth Management LLC lifted its holdings in shares of Natera by 0.5% in the 2nd quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company's stock worth $2,219,000 after buying an additional 66 shares during the period. Main Management ETF Advisors LLC raised its position in shares of Natera by 1.7% in the 2nd quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company's stock worth $743,000 after acquiring an additional 72 shares in the last quarter. Yousif Capital Management LLC raised its position in shares of Natera by 4.5% in the 3rd quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company's stock worth $271,000 after acquiring an additional 72 shares in the last quarter. Wedmont Private Capital raised its position in shares of Natera by 4.9% in the 2nd quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company's stock worth $256,000 after acquiring an additional 74 shares in the last quarter. Finally, Gries Financial LLC raised its position in shares of Natera by 4.0% in the 3rd quarter. Gries Financial LLC now owns 1,904 shares of the medical research company's stock worth $306,000 after acquiring an additional 74 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Piper Sandler reissued an "overweight" rating and set a $220.00 target price (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. Wells Fargo & Company assumed coverage on Natera in a research note on Monday, September 22nd. They set an "equal weight" rating and a $175.00 target price on the stock. Cowen reissued a "buy" rating on shares of Natera in a research note on Friday, August 8th. Barclays reissued an "overweight" rating and set a $210.00 target price (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. Finally, Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 price objective on the stock in a research note on Monday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $196.81.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.